



# Global Asset Allocation: The View From Europe

May 2021

## 1 Market Perspective

As of 30 April 2021



- Global economic growth is expected to begin peaking in the coming quarters as the impacts of economic reopening and fiscal stimulus are realised.
- Global inflation expectations are likely to trend higher as the consumer demand surge is met with signs of supply shortages and as the Fed promises to keep a zero interest rate policy until the labour market rebounds.
- Asian and European economies should benefit amid the recovery given their higher cyclical exposures, although recent resurgence in coronavirus cases in major Asian economies is a growing concern.
- Key risks to global markets include the resurgence in coronavirus cases, pace of vaccinations, rising inflation, geopolitical concerns, and potential for higher taxes as countries pivot to funding recovery costs.

## 2 Portfolio Positioning



- We increased our underweight in equities relative to bonds and cash as the risk/reward profile looks less compelling for equities after a strong rebound from March 2020 lows. Equities could be vulnerable to potential setbacks in the recovery, fading policy support and higher taxes.
- We increased the overweight of euro versus the US dollar. The recent dollar weakness should continue as the US policy stance remains very loose and the European re-opening accelerates in the spring. Europe is also a major beneficiary of the current global manufacturing boom.
- Within equities, we are further tilting into value globally, based on more attractive relative valuations and expectations for cyclical companies to continue to benefit from the improvement in growth from a recovering global economy—bolstered by fiscal stimulus in the US, increasing commodity prices and higher interest rates.


## 3 Market Themes

### Surprise

As first-quarter earnings season comes to an end, the biggest surprise has been the ‘surprises’ themselves, in terms of how much companies have beat earnings expectations. First-quarter expectations were for a near-20% increase in S&P 500 earnings, but companies have blown past that estimate, approaching a 45% year-over-year gain. Ironically, this was not the first quarter for massive surprises as companies have significantly exceeded expectations throughout most of the pandemic, particularly as many technology companies benefited exponentially early on from the lockdowns. The surprises this quarter, however, have been led by more cyclical companies in the energy and consumer discretionary sectors. While seemingly all positive news, price reaction to earnings beats was muted this quarter, suggesting investors may be rationalising high valuations with a normalisation in future earnings or perhaps the mounting pressure from rising input costs.

### S&P 500 Earnings Surprises<sup>1</sup>

As of 30 April 2021



Past performance is not a reliable indicator of future performance.

<sup>1</sup> Earnings surprises represent the aggregate percentage that S&P 500 reported quarterly earnings, which have exceeded expectations as of the close of the quarter.

<sup>2</sup> EM coronavirus cases represented by cases in India, Brazil and Argentina. EM vs. DM relative return represented by MSCI Emerging Markets Index and MSCI World Index, respectively.


Sources: Standard & Poor's, MSCI, and T. Rowe Price calculations using data from FactSet Research Systems Inc. All rights reserved. (See Additional Disclosures.)

### Crosscurrents

A renewed surge in coronavirus cases across several emerging markets (EM) countries—including India, Brazil, and Argentina—is weighing heavily on these economies as they struggle with insufficient medical infrastructure and access to vaccines. In addition, higher interest rates, rising inflation, a strengthening US dollar, and moderating growth in China have investors concerned about emerging markets prospects. EM have lagged developed markets (DM) year-to-date and with much of the economic recovery appearing priced into many DMs emerging markets may have more room to advance as the global recovery takes hold. With commodity prices still on the rise, expectations for a weaker US dollar, and a continued dovish stance from the Fed, we think emerging markets may be in a strong position to rebound—assuming that they can navigate the crosscurrents.

### EM vs. DM Relative Return & EM Coronavirus Cases<sup>2</sup>

As of 30 April 2021





 **Positives**

 **Negatives**

- 
- |  |  |
|--|--|
| <p><b>Europe</b></p> <ul style="list-style-type: none"><li>▪ Higher exposure to more cyclically oriented sectors that should benefit from economic recovery</li><li>▪ Lockdowns are being lifted in most countries</li><li>▪ Monetary and fiscal policies remain accommodative</li><li>▪ Equity valuations remain attractive relative to the US</li><li>▪ Stronger long-term euro outlook</li></ul>                  | <ul style="list-style-type: none"><li>▪ Vaccination effort facing supply shortages</li><li>▪ Limited long-term catalysts for growth</li><li>▪ Limited scope for European Central Bank (ECB) to stimulate further</li><li>▪ Brexit likely to negatively impact trade</li></ul>  |
| <p><b>United Kingdom</b></p> <ul style="list-style-type: none"><li>▪ Rapid vaccination means that the economy could return closer to normal by autumn, two to three months ahead of eurozone countries</li><li>▪ Lockdown exit strategy is now firmly in place</li><li>▪ Fiscal furlough extension and investment tax super deduction to support strong recovery</li><li>▪ A Brexit deal has been achieved</li></ul> | <ul style="list-style-type: none"><li>▪ Brexit transition and third lockdown could slow down the pace of economic recovery</li><li>▪ Demand risks from a delayed, but likely very large, fiscal consolidation in two to three years remain</li><li>▪ The Bank of England remains very hawkish in light of strong real economy data</li><li>▪ Overheating housing market could pose future financial stability risk</li></ul> |
| <p><b>United States</b></p> <ul style="list-style-type: none"><li>▪ Pace of vaccinations has been strong</li><li>▪ Monetary policy remains very accommodative</li><li>▪ More fiscal support on the way</li><li>▪ Healthy consumer balance sheets and high savings rate</li></ul>   | <ul style="list-style-type: none"><li>▪ Elevated stock and bond valuations</li><li>▪ High corporate and government debt levels</li><li>▪ Corporate taxes likely to rise</li><li>▪ Unemployment remains elevated</li></ul>  |
-

 **Positives** **Negatives**

- Japan**
- Leading economic indicators are breaking through the expansion levels. Employment and retail sales data are surprising on the upside
  - Domestic stocks are a global reflation play, with positive correlations to Purchasing Managers' Indices and bond yields
  - Earnings revision ratios are close to record levels

- Price momentum in equity markets is calling for a pause in the appreciation trend in the near term
- COVID-19 vaccines are being administered late relative to other countries, while the pandemic is still not yet under control
- Bank of Japan dropped the annual exchange-traded fund buying target, causing some concerns regarding its ability to remain the buyer of last resort

**Asia Pacific  
ex-Japan**

- Chinese economic growth remains solid, with domestic consumption progressively replacing industrial production as the main driver
- Policy targets in China (e.g., growth and fiscal deficit) allow for some flexibility on the path to normalisation
- Economic data in Australia, such as business conditions and companies' profitability, continue to beat multi-decade records
- The Reserve Bank of Australia remains extremely dovish, indicating any policy organisation may be a long way off


- Early signs of inflationary pressures and supply bottlenecks in China are concerning; economic momentum may have peaked in Q1
- Chinese policymakers' focus on deleveraging the economy creates some concerns for certain companies, although this is not a systemic risk
- Slow COVID-19 vaccine rollout is a concern in Australia as the winter season approaches
- Early signs of inflationary pressures seen in Australian housing and construction markets

**Emerging  
Markets**

- Exposure to cyclical areas of the economy should benefit from broad global recovery
- Commodity prices rising
- Chinese economy remains strong
- Equity valuations attractive relative to developed markets

- Very concerning coronavirus outbreak in India
- Vaccine supply and distribution infrastructure are well behind developed markets
- Stimulus from China likely to fade going forward
- Limited ability to enact fiscal stimulus (excluding China)


**Past performance is not a reliable indicator of future performance.**



**Past performance is not a reliable indicator of future performance.**

\*Includes Australia.

<sup>1</sup> For pairwise decisions in style and market capitalisation, positioning within boxes represents positioning in the first-mentioned asset class relative to the second asset class.



Past performance is not a reliable indicator of future performance.



## EUROPEAN INVESTMENT COMMITTEE



**Quentin Fitzsimmons**  
Senior Portfolio Manager,  
Fixed Income Division



**Andrew Keirle**  
Portfolio Manager, Emerging  
Markets Local Currency Bonds



**Yoram Lustig**  
Head of Multi-Asset  
Solutions, EMEA



**Ken Orchard**  
Senior Portfolio Manager,  
Fixed Income Division



**David Stanley**  
Portfolio Manager,  
European Corporate Bonds



**Toby Thompson**  
Portfolio Manager,  
Multi-Asset Division



**Mitchell Todd**  
Co-head of EMEA Equity



**Michael Walsh**  
Solutions Strategist, EMEA



**Tomasz Wieladek**  
International Economist

The specific securities identified and described are for informational purposes only and do not represent recommendations.

T. Rowe Price focuses on delivering investment management excellence that investors can rely on—now and over the long term.

## T.RowePrice<sup>®</sup>

### Additional Disclosures

Source: Unless otherwise stated, all market data are sourced from FactSet. Financial data and analytics provider FactSet. Copyright 2021 FactSet. All Rights Reserved.

Source: MSCI. MSCI and its affiliates and third party sources and providers (collectively, "MSCI") makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used as a basis for other indices or any securities or financial products. This report is not approved, reviewed, or produced by MSCI. Historical MSCI data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. None of the MSCI data is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such.

The "S&P 500 Index" is a product of S&P Dow Jones Indices LLC, a division of S&P Global, or its affiliates ("SPDJ") and has been licensed for use by T. Rowe Price. Standard & Poor's<sup>®</sup> and S&P<sup>®</sup> are registered trademarks of Standard & Poor's Financial Services LLC, a division of S&P Global ("S&P"); Dow Jones<sup>®</sup> is a registered trademark of Dow Jones Trademark Holdings LLC ("Dow Jones"). This product is not sponsored, endorsed, sold or promoted by SPDJI, Dow Jones, S&P or their respective affiliates, and none of such parties make any representation regarding the advisability of investing in such product(s) nor do they have any liability for any errors, omissions, or interruptions of the S&P 500 Index.

### Important Information

**This material is being furnished for general informational and/or marketing purposes only.** This material is being furnished for general informational purposes only. The material does not constitute or undertake to give advice of any nature, including fiduciary investment advice, nor is it intended to serve as the primary basis for an investment decision. Prospective investors are recommended to seek independent legal, financial and tax advice before making any investment decision. T. Rowe Price group of companies including T. Rowe Price Associates, Inc. and/or its affiliates receive revenue from T. Rowe Price investment products and services. **Past performance is not a reliable indicator of future performance.** The value of an investment and any income from it can go down as well as up. Investors may get back less than the amount invested.

The material does not constitute a distribution, an offer, an invitation, a personal or general recommendation or solicitation to sell or buy any securities in any jurisdiction or to conduct any particular investment activity. The material has not been reviewed by any regulatory authority in any jurisdiction.

Information and opinions presented have been obtained or derived from sources believed to be reliable and current; however, we cannot guarantee the sources' accuracy or completeness. There is no guarantee that any forecasts made will come to pass. The views contained herein are as of the date written and are subject to change without notice; these views may differ from those of other T. Rowe Price group companies and/or associates. Under no circumstances should the material, in whole or in part, be copied or redistributed without consent from T. Rowe Price.

The material is not intended for use by persons in jurisdictions which prohibit or restrict the distribution of the material and in certain countries the material is provided upon specific request.

It is not intended for distribution to retail investors in any jurisdiction.

**DIFC**—Issued in the Dubai International Financial Centre by T. Rowe Price International Ltd. This material is communicated on behalf of T. Rowe Price International Ltd. by its representative office which is regulated by the Dubai Financial Services Authority. For Professional Clients only.

**EEA ex-UK**—Unless indicated otherwise this material is issued and approved by T. Rowe Price (Luxembourg) Management S.à r.l. 35 Boulevard du Prince Henri L-1724 Luxembourg which is authorised and regulated by the Luxembourg Commission de Surveillance du Secteur Financier. For Professional Clients only.

**Switzerland**—Issued in Switzerland by T. Rowe Price (Switzerland) GmbH, Talstrasse 65, 6th Floor, 8001 Zurich, Switzerland. For Qualified Investors only.

**UK**—This material is issued and approved by T. Rowe Price International Ltd, 60 Queen Victoria Street, London, EC4N 4TZ which is authorised and regulated by the UK Financial Conduct Authority. For Professional Clients only.

© 2021 T. Rowe Price. All Rights Reserved. T. ROWE PRICE, INVEST WITH CONFIDENCE, and the Bighorn Sheep design are, collectively and/or apart, trademarks of T. Rowe Price Group, Inc.